Daiichi Sankyo’s Quizartinib Voted Down by US FDA Advisory Committee

The US FDA’s Oncologic Drugs Advisory Committee voted down Daiichi Sankyo’s oral selective type II FLT3 inhibitor quizartinib for the treatment of adults with relapsed / refractory FLT3-ITD acute myeloid leukemia (AML), which is currently under regulatory review by the...read more